acceleron pharma nasdaq xlrn shares are trading higher after bloomberg reported the company is in talks for a potential 11 billion buyout according to people familiar with the matter acceleron could be acquired by a large pharmaceutical company for about 180 a share in cash bloomberg reported however bloomberg was unable to identify any bidders in the deal  acceleron pharma is a biotechnology company focused on the discovery development and commercialization of novel therapies the companys research focuses on key natural regulators of cellular growth and repair at last check acceleron pharma was trading 557 higher at 17698 per share the stock has a 52week high of 17423 and a 52week low of 9998